Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer
Clinical trial NCT02481050 · COMPLETED
Trial details
- NCT number
- NCT02481050
- Sponsor
- Eisai Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-06-16
- Primary completion
- 2016-12-31
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.